Immune checkpoint inhibitors are associated with a heterogeneous spectrum of cardiovascular toxicities, including a rare but potentially fatal myocarditis that often co-occurs with myositis and myasthenia gravis.
Provides a clinically oriented overview and case-based guide for the diagnosis and management of immune checkpoint inhibitor-related cardiovascular toxicity, particularly myocarditis.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.
Raschi et al. (Wed,) conducted a review in Cancer patients receiving immune checkpoint inhibitors. Immune checkpoint inhibitors (ICIs) was evaluated. Immune checkpoint inhibitors are associated with a heterogeneous spectrum of cardiovascular toxicities, including a rare but potentially fatal myocarditis that often co-occurs with myositis and myasthenia gravis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: